Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4164—1,3-Diazoles
  • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/425—Thiazoles
  • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/433—Thidiazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
  • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
  • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
  • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D277/38—Nitrogen atoms
  • C07D277/50—Nitrogen atoms bound to hetero atoms
  • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
  • C07D285/01—Five-membered rings
  • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
  • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
  • C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
  • C07D285/01—Five-membered rings
  • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
  • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
  • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
  • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
  • C07D493/04—Ortho-condensed systems

Definitions

• Voltage-gated sodium (NaV) channels are responsible for the upstroke of the action potential in most excitable cells, including nerve cells [Hille, B. Ion channels of excitable membranes. (2001), 3 rd ed, Sinauer Associates, Sunderland, MA].
• NaV channels open in response to membrane depolarization and generate an inward current that underlies the upstroke of the action potential.
• NaV channels open quickly (within msec) in response to depolarization and then just as rapidly close by a process called inactivation.
• these channels can exist in several different conformations or 'states' whose occupancy is governed by membrane voltage.
• NaV channels are composed of a pore-forming alpha subunit responsible for ion conduction and gating [Catterall, WA, J. Physiol. 590(11): 2577-2599, (2012)]. These large single polypeptides (>250 kDa) are organized into four functional domains (DI- DIV), each with 6 transmembrane segments (S1-S6). Each domain can be further subdivided into the voltage-sensor domain (VSD) comprised of segments S1-S4 and the pore domain comprised of segments S5-S6.
• VSD voltage-sensor domain
• NaV channels have associated beta subunits which have a single transmembrane segment and a large extracellular immunoglobin-like region.
• Beta subunits modulate expression, gating and localization of the alpha subunit and interact with the extracellular matrix and intracellular cytoskeleton [Isom, LL, Neuroscientist, 7(l):42-54, (2001)].
• NaV 1.1- NaV 1.9 Goldin, AL et al., Neuron 28(2): 365-368, (2000).
• individual NaVl family members are characterized by specific gating properties, localization and pharmacology [Catterall, WA, Goldin AL and SG Waxman, Pharmacol. Rev. 57(4):397- 409, (2005)].
• NaV1.5 is expressed almost exclusively in the heart and is weakly sensitive to the neurotoxin tetrodotoxin (TTX).
• TTX neurotoxin tetrodotoxin
• NaV1.7 is mostly expressed in peripheral sensory neurons and is TTX-sensitive.
• a second sub-family of NaVs channels (NaV2/NaG) also exists [Wantanabe, E et al, J. Neurosci., 20(20):7743- 7751, (2000)].
• Site 1 binds the pore-blockers tetrodotoxin and saxitoxin and is formed by residues of the pore loops of all four domains [Noda, M et al., FEBS Lett. 259(1):213-216, (1989); Terlau, H et al, FEBS Lett. 293(l-2):93-96, (1991)].
• Site 2 binds lipid soluble toxins like veratridine and batrachotoxin and maps to S6 residues in Dl and DIV [Trainer, VL et al, J. Biol. Chem. 271(19): 11261-11267, (1996); Kimura, T et al. FEBS Lett.
• Alpha scorpion toxins bind to Site 3 which includes the S3-S4 loop of DIV [Rogers, JC et al, J. Biol. Chem. 271: 15950- 15962, (1996)].
• Site 4 binds beta scorpion toxins and includes the S3-S4 loop of DII [Cestele, S et al, J. Biol. Chem. 282:21332-21344, (1998)].
• Site 5 is where the so-called red-tide toxins like brevetoxin bind and includes the S6 of Dl and S5 of DIV [Trainer, VL et al, Mol. Pharmacol. 40(6):988-994, (1991); Trainer, VL et al, J. Biol.
• the present disclosure relates to compounds of formula I, which inhibit NaV 1.7, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods of using and making such compounds and compositions.
• One aspect of the invention is a compound of formula I where:
• A is N(R 4 )(R 5 ) or OR 4 ;
• R 1 is thiazolyl or thiadiazolyl and is substituted with 0-2 substituents selected from cyano, halo, alkyl, haloalkyl, alkoxy, and haloalkoxy;
• R 2 is cyano, halo, alkyl, haloalkyl, alkoxy, or haloalkoxy;
• R 3 is cyano, halo, alkyl, haloalkyl, alkoxy, or haloalkoxy;
• R 4 is alkyl, (cycloalkyl)alkyl, or cycloalkyl, and is substituted with 0-2 substituents selected from hydroxyalkyl, alkoxyalkyl, (Ar ⁇ alkyl, hydroxy, alkoxy, tetrahydrofuranyl, tetrahydropyranyl, hexahydrofurofuranyl, and Ar 1 ; or R 4 is (R 6 R 7 N)alkyl, ((R 6 R 7 N)cycloalkyl)alkyl, (((R 6 R 7 N)alkyl)cycloalkyl)alkyl, (R 6 R 7 N)cycloalkyl, ((R 6 R 7 N)alkyl)cycloalkyl, or (R 6 R 7 N), and is substituted with 0-3 halo or alkyl substituents, and with 0-1 Ar 1 or (Ar ⁇ alkyl substituents; or R 4 is a [l-4.1-4.0-2]bridgedb
• R 5 is hydrogen or alkyl; or NR 4 R 5 taken together is azetidinyl, pyrrolidinyl, piperidinyl, piperidinonyl, piperazinyl, or morpholinyl, and is substituted with 0-1 NR 6 R 7 substituents and also with 0-5 halo or alkyl substituents; or NR 4 R 5 taken together is a [l-4.1-4.0-2]bridgedbicyclicdiamine with 0-3 halo or alkyl substituents;
• R 6 is hydrogen, alkyl, or cycloalkyl
• R 7 is hydrogen, alkyl, or cycloalkyl
• NR 6 R 7 taken together is azetidinyl, pyrrolidinyl, piperidinyl, piperidinonyl, piperazinyl, or morpholinyl, and is substituted with 0-5 halo, hydroxyl, alkyl, hydroxyalkyl, or alkoxyalkyl substituents; or NR 6 R 7 taken together is oxaazaspirodecanyl; and
• Ar 1 is phenyl substituted with 0-5 substituents selected from cyano, halo, alkyl, haloalkyl. alkoxy, and haloalkoxy; or a pharmaceutically acceptable salt thereof.
• Another aspect of the invention is a compound of formula I where R 1 is thiazolyl or thiadiazolyl.
• Another aspect of the invention is a compound of formula I where R 2 and R 3 are halo.
• Another aspect of the invention is a compound of formula I where R 4 is alkyl, (cycloalkyl)alkyl, or cycloalkyl, and is substituted with 0-2 substituents selected from hydroxyalkyl, alkoxyalkyl, hydroxy, alkoxy, tetrahydrofuranyl, tetrahydropyranyl, and hexahy drofurofurany 1.
• R 4 is alkyl, (cycloalkyl)alkyl, or cycloalkyl, and is substituted with 0-2 substituents selected from hydroxyalkyl, alkoxyalkyl, hydroxy, alkoxy, tetrahydrofuranyl, tetrahydropyranyl, and hexahy drofurofurany 1.
• R 4 is alkyl, (cycloalkyl)alkyl, or cycloalkyl, and is substituted with 0-2 substituents selected from hydroxyalkyl, alk
• Another aspect of the invention is a compound of formula I where R 4 is a
• Another aspect of the invention is a compound of formula I where A is N(R 4 )(R 5 ).
• Another aspect of the invention is a compound of formula I where A is OR 4 .
• variable substituent including A, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and Ar 1
• the invention includes combinations of the different aspects.
• Alkyl means a straight or branched alkyl group composed of 1 to 6 carbons.
• Alkenyl means a straight or branched alkyl group composed of 2 to 6 carbons with at least one double bond.
• Alkynyl means a straight or branched alkyl group composed of 2 to 6 carbons with at least one triple bond.
• Cycloalkyl means a monocyclic ring system composed of 3 to 7 carbons. Terms with a hydrocarbon moiety (e.g. alkoxy) include straight and branched isomers for the hydrocarbon portion which are composed of 1 to 6 carbons.
• Halo includes fluoro, chloro, bromo, and iodo.
• Haloalkyl and haloalkoxy include all halogenated isomers from monohalo to perhalo
• Aryl means a monocyclic or bicyclic aromatic ring system having 5 to 12 carbon atoms wherein one or both of the rings are aromatic. Representative examples of aryl groups include, but are not limited to, indanyl, indenyl, naphthyl, phenyl, and tetrahydronaphthyl.
• Heteroaryl means a 5 to 7 membered monocyclic or 8 to 1 1 membered bicyclic aromatic ring system with 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur. Where a bonding attachment location is not specified, the bonding may be attached at any appropriate location as understood by practitioners in the art. Combinations of substituents and bonding patterns are only those that result in stable compounds as understood by practitioners in the art. Parenthetic and multiparenthetic terms are intended to clarify bonding relationships to those skilled in the art. For example, a term such as ((R)alkyl) means an alkyl substituent further substituted with the substituent R.
• the invention includes all pharmaceutically acceptable salt forms of the compounds.
• Pharmaceutically acceptable salts are those in which the counter ions do not contribute significantly to the physiological activity or toxicity of the compounds and as such function as pharmacological equivalents. These salts can be made according to common organic techniques employing commercially available reagents.
• Some anionic salt forms include acetate, acistrate, besylate, bromide, chloride, citrate, fumarate, glucouronate, hydrobromide, hydrochloride, hydroiodide, iodide, lactate, maleate, mesylate, nitrate, pamoate, phosphate, succinate, sulfate, tartrate, tosylate, and xinofoate.
• Some cationic salt forms include ammonium, aluminum, benzathine, bismuth, calcium, choline, diethylamine, diethanolamine, lithium, magnesium, meglumine,
• the invention includes all stereoisomeric forms of the compounds including enantiomers and diastereomers. Methods of making and separating stereoisomers are known in the art.
• the invention includes all tautomeric forms of the compounds.
• the invention includes atropisomers and rotational isomers.
• the invention is intended to include all isotopes of atoms occurring in the present compounds.
• Isotopes include those atoms having the same atomic number but different mass numbers.
• isotopes of hydrogen include deuterium and tritium.
• Isotopes of carbon include 1 C and 14 C.
• Isotopically- labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed. Such compounds may have a variety of potential uses, for example as standards and reagents in determining biological activity. In the case of stable isotopes, such compounds may have the potential to favorably modify biological, pharmacological, or pharmacokinetic properties.
• PPC Ion Works Barracuda population patch clamp
• NaV1.7 currents were elicited by a voltage clamp protocol designed to bias the NaV1.7 channels to their inactivated state as follows. From holding potential of -60 mV cells were briefly hyperpolarized to -lOOmV for 1.25 sec, then stepped to -20mV for 20 sec to inactivate the channels. This was followed by a relatively brief hyperpolarizati on to - lOOmv for 300 ms, then a 20 msec test pulse to -20mV to elicit the NaV1.7 current used to measure the pharmacology of all test compounds. Compounds were incubated for 600 sec between the pre- and post-compound reads.
• the external recording solution used was (in mM) 137 NaCl, 4 KC1, 1 MgC12, 1.8 CaC12, 10 Hepes, 10 glucose, pH to 7.4 with NaOH, and the internal solution used was (in mM) 100 K-gluconate, 40KC1, 3.2 MgC12, 5 EGTA, 10 HEPES pH to 7.2 with KOH.
• the same solutions were used to record NaV1.5 currents, with the following voltage clamp protocol. NaV1.5 currents were elicited by a voltage clamp protocol designed to bias the NaV1.5 channels to their inactivated state as follows.
• HEK 293 cells expressing NaV1.7 and NaV1.5 channels were used (Essen Biosciences, Ann Arbor, Michigan). Cells were cultured in T-175 flasks and passaged every 2 to 3 days at 1 :3 to 1 :6 seeding density dilutions. Cells were grown to 70% to 90% confluence in a flask and removed from the incubator (37° C, 5% C02) 1 to 3 days after plating. Growth medium was aspirated from the culture flasks. Cells were gently rinsed with 10 ml of PBS (Catalog number: 14190144, Gibco) to remove residual media.
• PBS Catalog number: 14190144, Gibco
• the cell supernatant was decanted, and the cell pellets were resuspended in 5-6 mL of external solution followed by gentle triturations using a 10 ml pipette, and transferred to a 15 ml conical tube and immediately brought to the IW Barracuda instrument.
• the cell suspension had a final concentration of ⁇ 2 to 3 million cells per ml; this corresponds to 10,000 cells added per well. Peak membrane currents were analyzed with IW Barracuda software and exported to
• Ligand Binding Assay (LBA): hNaV1.7 binding affinities were determined with a filtration binding assay using purified membranes from HEK293 cells stably expressing hNaV1.7.
• HEK293 cells from a 10-stack cell culture flask (approximately 10 10 cells) were dissociated, frozen, and stored at -80 ° C. To prepare membranes, the frozen cell pellet was thawed and suspended in 6 ml hypotonic lysis buffer (50 mM HEPES, 0.1% mammalian protease inhibitor cocktail).
• Purified membranes were aliquoted, flash frozen in an ethyl alcohol dry ice bath, and stored at - 80 ° C.
• 50 ⁇ g of purified hNaV1.7 HEK cell membranes were incubated with test compounds (eight concentrations, in duplicate) and 0.5 nM [3H] labeled radioligand in a 96 well plate for 24 hours at room temperature on a shaker.
• the total binding reaction volume was 250 ⁇ , consisting of 200 ⁇ purified hNaV1.7 HEK cell membranes, 25 ⁇ test compound, and 25 ⁇ radioligand.
• Non-specific binding was defined by 20 ⁇ of a reference hNaV1.7 inhibitor.
• Binding reactions were terminated by filtration through GF/B filters presoaked in 0.5% polyethyleneamine. Filters were washed 5 times with 2 ml each of 4 ° C wash buffer (50 mM Tris-HCl, pH 7.4 at 4°C). Bound radioactivity captured on the filters was counted on a liquid scintillation counter. Specific binding, expressed as % inhibition, was fit with Graphpad Prism software to determine binding IC50 values. Results are reported in Table 1 (NaV1.7 LB A IC50 in nM).
• Another aspect of the invention is a pharmaceutical composition
• a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
• Another aspect of the invention is a method for treating pain in a patient comprising administering a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, with a pharmaceutically acceptable carrier.
• Another aspect of the invention is the use of a compound of formula I in the manufacture of a medicament for the treatment of pain.
• “Therapeutically effective” means the amount of agent required to provide a meaningful patient benefit as understood by practitioners in the field of pain.
• Patient means a person afflicted with pain and suitable for therapy as understood by practitioners in the field.
• Treatment means a person afflicted with pain and suitable for therapy as understood by practitioners in the field.
• Treatment means a person afflicted with pain and suitable for therapy as understood by practitioners in the field.
• Treatment means a person afflicted with pain and suitable for therapy as understood by practitioners in the field.
• Treatment means a person afflicted with pain and suitable for therapy as understood by practitioners in the field.
• therapy means a person afflicted with pain and suitable for therapy as understood by practitioners in the field.
• radiation means a person afflicted with pain and suitable for therapy as understood by practitioners in the field.
• radiation means a person afflicted with pain and suitable for therapy as understood by practitioners in the field.
• radiation means a person afflicted with pain and suitable for therapy as understood by practitioners in the field.
• radiation means a person afflicted with pain and suitable for therapy as understood by practitioners in the field.
• radiation means a
• compositions comprised of a therapeutically effective amount of a compound of Formula I or its pharmaceutically acceptable salt and a pharmaceutically acceptable carrier and may contain conventional excipients.
• a therapeutically effective amount is that which is needed to provide a meaningful patient benefit.
• Pharmaceutically acceptable carriers are those conventionally known carriers having acceptable safety profiles.
• Compositions encompass all common solid and liquid forms including capsules, tablets, losenges, and powders as well as liquid suspensions, syrups, elixers, and solutions. Compositions are made using common formulation techniques, and conventional excipients (such as binding and wetting agents) and vehicles (such as water and alcohols) are generally used for compositions. See, for example, Remington 's Pharmaceutical Sciences, 17th edition, Mack Publishing Company, Easton, PA (1985).
• Solid compositions are normally formulated in dosage units and compositions providing from about 1 to 1000 mg of the active ingredient per dose are preferred. Some examples of dosages are 1 mg, 10 mg, 100 mg, 250 mg, 500 mg, and 1000 mg.
• Liquid compositions are usually in dosage unit ranges. Generally, the liquid composition will be in a unit dosage range of 1-100 mg/mL. Some examples of dosages are 1 mg/mL, 10 mg/mL, 25 mg/mL, 50 mg/mL, and 100 mg/mL.
• the invention encompasses all conventional modes of administration; oral and parenteral methods are preferred.
• the dosing regimen will be similar to other agents used clinically. Typically, the daily dose will be 1-100 mg/kg body weight daily. Generally, more compound is required orally and less parenterally. The specific dosing regime, however, will be determined by a physician using sound medical judgement.
• the compounds of this invention can be made by various methods known in the art including those of the following schemes and in the specific embodiments section.
• the structure numbering and variable numbering shown in the synthetic schemes are distinct from, and should not be confused with, the structure or variable numbering in the claims or the rest of the specification.
• the variables in the schemes are meant only to illustrate how to make some of the compounds of this invention.
• the disclosure is not limited to the foregoing illustrative examples and the examples should be considered in all respects as illustrative and not restrictive, reference being made to the claims, rather than to the foregoing examples, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced.
• NBS N-bromosuccinimide
• min for minutes; h for hours
• MeCN or ACN for acetonitrile
• EtOAc for ethyl acetate
• DEAD for diethyl azodicarboxylate
• DIAD diisopropyl azodicarboxylate
• DMSO for dimethylsulfoxide
• LCMS or LC/MS for liquid chromatography -mass spectrometry, NMR for nuclear magnetic resonance, TLC for thin layer chromatography, UV for ultraviolet; Rt for retention time.
• Method A Column: Waters Acquity UPLC BEH CI 8, 2.1 x 50 mm, 1.7- ⁇ particles; Mobile Phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate; Temperature: 50 °C; Gradient: 0-100% B over 3 minutes, then a 0.75-minute hold at 100% B; Flow: 1.0 mL/min;
• Method B Column: Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7- ⁇ particles; Mobile Phase A: 5:95 acetonitrile:water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile:water with 0.1% trifluoroacetic acid; Temperature: 50 °C; Gradient: 0- 100% B over 3 minutes, then a 0.75-minute hold at 100% B; Flow: 1.0 mL/min;
• Method C Column: Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7- ⁇ particles; Mobile Phase A: 5:95 methanol: water with 10 mM ammonium acetate; Mobile Phase B: 95:5 methanol: water with 10 mM ammonium acetate; Temperature: 50 °C; Gradient: 0- 100% B over 3 minutes, then a 0.75-minute hold at 100% B; Flow: 1.0 mL/min;
• Scheme I describes a general synthesis of compounds of formula 1.
• Treatment of 4-fluoro-benzenesulfonamides 2 with an amine of fomula B-A(NH2) or an alcohol of formula B-A(OH) in the presence of a base such as lithium bis(trimethylsilyl)amide or potassium carbonate in an appropriate solvent such as DMF or THF can afford 4- substituted benzenesulfonamides 2.
• Compounds of formula 2 can be converted to compounds of formula 1 by treatment with an acid such as trifluoroacetic acid in an appropriate solvent such as dichloromethane.
• Typical Mitsunobo conditions include triphenyl phosphine and an azodicarboxylate such as diethyl azodicarboxylate (DEAD) or diisopropyl azodicarboxylate (DIAD) in an appropriate solvent such as THF.
• DEAD diethyl azodicarboxylate
• DIAD diisopropyl azodicarboxylate
• Compounds of formula 2 can be converted to compounds of formula 1 by treatment with an acid such as trifluoroacetic acid in an appropriate solvent such as dichloromethane.
• Step A 4-((l,4-dioxaspiro[4.5]decan-8- ylmethyl)amino)-5-chloro-N-(2,4-dimethoxybenzyl)-2-fluoro-N-(thiazol-2- yl)benzenesulfonamide:A suspension of l,4-dioxaspiro[4.5]decan-8-ylmethanamine (0.43 g, 2.51 mmol), 5-chloro-N-(2,4-dimethoxybenzyl)-2,4-difluoro-N-(thiazol-2- yl)benzenesulfonamide (1.157 g, 2.51 mmol) and cesium carbonate (0.859 g, 2.64 mmol) in DMF (25.1 ml) was stirred at rt for 12 h.
• Step B 5-chloro-2-fluoro-4-(((4- oxocyclohexyl)methyl)amino)-N-(thiazol-2-yl)benzenesulfonamide: A solution of 4- ((l ,4-dioxaspiro[4.5]decan-8-ylmethyl)amino)-5-chloro-N-(2,4-dimethoxybenzyl)-2- fluoro-N-(thiazol-2-yl)benzenesulfonamide (1.18 g, 1.928 mmol) and HC1 (7.71 ml, 7.71 mmol) in acetone (24.10 ml) was heated under reflux for 2 h.
• Step C 5-chloro-4-(((4- (cyclopropylainino)cyclohexyl)methyl)amino)-2-fluoro-N-(thiazol-2- yl)benzenesulfonamide (single isomer): A mixture of 5-chloro-2-fluoro-4-(((4- oxocyclohexyl)methyl)amino)-N-(thiazol-2-yl)benzenesulfonamide (50 mg, 0.120 mmol), cyclopropanamine (83 ⁇ , 1.196 mmol), sodium cyanoborohydride (30.1 mg, 0.479 mmol) and zinc chloride (1.631 mg, 0.012 mmol) in ethanol (798 ⁇ ) was stirred at rt for 12 h.
• Ethanol was removed in vacuo, and the residue was purified via preparative LC/MS with the following conditions: Column: XBridge C I 8, 19 x 200 mm, 5- ⁇ particles; Mobile Phase A: 5 :95 methanol: water with 10-mM ammonium acetate; Mobile Phase B: 95 :5 methanol: water with 10-mM ammonium acetate; Gradient: 20-60% B over 27 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation.
• Step A methyl 4-(benzyloxy)-2-(2-(benzyloxy)ethyl)-2- cyanobutanoate.
• Step B 2- (aminomethyl)-4-(benzyloxy)-2-(2-(benzyloxy)ethyl)butan-l-ol: To a solution of methyl 4-(benzyloxy)-2-(2-(benzyloxy)ethyl)-2-cyanobutanoate (400 mg, 1.09 mmol) THF (5 mL) and ether (5 mL) at rt was added lithium aluminum hydride (83 mg, 2.177 mmol), and the reaction mixture was heated under reflux for 4 h. Sodium sulfate decahydrate was added, and the reaction mixture was stirred at rt for 1 h.
• Step C tert-butyl (4-(benzyloxy)-2-(2-(benzyloxy)ethyl)-2- (hydroxymethyl)butyl)carbamate: To a solution of 2-(aminomethyl)-4-(benzyloxy)-2-(2- (benzyloxy)ethyl)butan-l-ol (830 mg, 0.41 mmol) DCM (5 mL) at rt was added BOC- anhydride (0.617 mL, 2.66 mmol), and the reaction mixture was stirerd at rt for 5 h.
• Step D tert-butyl (4-(benzyloxy)-2-(2-(benzyloxy)ethyl)-2-formylbutyl)carbamate: A solution of oxalyl dichloride (209 ⁇ , 2.401 mmol) in DCM (5335 ⁇ ) was cooled to -78°C and a solution of DMSO (318 ⁇ , 4.48 mmol) in CH2C12 (5335 ⁇ ) was added dropwise.
• Step E tert-butyl ((hexahydrofuro[2,3-b]furan-3a-yl)methyl)carbamate: A suspension of tert- butyl (4-(benzyloxy)-2-(2-(benzyloxy)ethyl)-2-formylbutyl)carbamate (27 mg, 0.061 mmol) and palladium hydroxide on carbon (17.17 mg, 0.122 mmol) in methanol (3057 ⁇ ) was hydrogenated with a hydrogen baloon for 1 h.
• Step F of (hexahydrofuro[2,3-b]furan-3a-yl)methanamine: To a solution of tert-butyl ((hexahydrofuro[2,3-b]furan-3a-yl)methyl)carbamate (15 mg, 0.062 mmol) in DCM (1233 ⁇ ) at rt was added TFA (95 ⁇ , 1.233 mmol), and the reaction mixture was stirred at rt for 3 h. The colvents were removed to give (hexahydrofuro[2,3- b]furan-3a-yl)methanamine (10 mg, 0.070 mmol, 113 % yield) as yellowish oil.
• Step G 5-chloro-N-(2,4-dimethoxybenzyl)-2-fluoro-4- (((hexahydrofuro[2,3-b]furan-3a-yl)methyl)andno)-N-(thiazol-2-yl)benzenesulfonamide: A mixture of (hexahydrofuro[2,3-b]furan-3a-yl)methanamine (9 mg, 0.063 mmol), 5- chloro-N-(2,4-dimethoxybenzy l)-2,4-difluoro-N-(thiazol-2-y l)benzenesulfonamide (31.9 mg, 0.069 mmol) and cesium carbonate (45.1 mg, 0.138 mmol) in DMF (629
• Step H 5-chloro-2-fluoro-4- (((hexahydrofuro[2,3-b]furan-3a-yl)methyl)andno)-N-(thiazol-2-yl)benzenesulfonamide: A solution of 5-chloro-N-(2,4-dimethoxybenzyl)-2-fluoro-4-(((hexahydrofuro[2,3- b]furan-3a-yl)methyl)amino)-N-(thiazol-2-yl)benzenesulfonamide (20 mg, 0.034 mmol) and TFA (0.05 mL) in DCM (342 ⁇ ) was stirred at rt for 1 h.
• Step A 1-tert-Butyl 4-methyl 4-(4-chlorophenyl)piperi dine- 1,4- dicarboxylate: to a slotion of l-(tert-butoxycarbonyl)-4-(4-chlorophenyl)piperidine-4- carboxylic acid (296 mg, 0.871 mmol) in methanol (2904 ⁇ ) at rt was added
• Step B tert- butyl 4-(4-chlorophenyl)-4-(hydroxymethyl)piperidine-l-carboxylate: to a solution of 1- tert-butyl 4-methyl 4-(4-chlorophenyl)piperi dine- 1 ,4-dicarboxy late (330 mg, 0.933 mmol) in ether (9326 ⁇ ) at 0 °C was added lithium aluminum hydride (53.1 mg, 1.399 mmol) portionwise, and the reaction mixture was stirred at 0 °C for 3 h. 20 mL ether was added, followed by sodium sulfate decahydrate (451 mg, 1.399 mmol).
• Step C tert-butyl 4-(4-chlorophenyl)-4-formylpiperidine-l-carboxylate: a solution of oxalyl dichloride (96 ⁇ , 1.105 mmol) in DCM (2455 ⁇ ) was cooled to -78°C and a solution of DMSO (146 ⁇ , 2.062 mmol) in DCM (2455 ⁇ ) was added dropwise. The mixture was stirred for 10 min, and a solution of tert-butyl 4-(4-chlorophenyl)-4- (hydroxymethyl)piperidine-l-carboxylate (240 mg, 0.737 mmol) in DCM (2455 ⁇ ) was added dropwise.
• Step D tert-Butyl 4-(4-chlorophenyl)-4- vinylpiperidine-l-carboxylate: to a suspension of methyl(triphenyl)phosphonium (543 mg, 1.956 mmol) in THF (1 mL) at -78 °C was added «-BuLi (783 ⁇ , 1.956 mmol) dropwise, and a orange milky suspension was formed. The reaction mixture was removed, and the mixture was stirred at 0 C for 30 min.
• Step E tert-Butyl 4-(4- chlorophenyl)-4-(2-hydroxyethyl)piperidine-l-carboxylate: to a solution of tert-butyl 4- (4-chloropheny l)-4-vinylpiperi dine- 1-carboxy late (100 mg, 0.311 mmol) in THF (777 ⁇ ) at 0 °C was added borane THF complex (621 ⁇ , 0.621 mmol) and the reaction mixture was stirred at 0 °C for 1 h. Hydrogen peroxide (37%, 0.30 mL ) and IN NaOH (1 mL) was added, and the reaction mixture was stirred at rt for 1 h.
• Step F tert-butyl 4-(4-chlorophenyl)-4-(2- (4-(N-(2,4-dimethoxybenzyl)-N-(l,2,4-thiadiazol-5-yl)sulfamoyl)-2,5- difluorophenoxy)ethyl)piperidine-l-carboxylate: to a solution of tert-butyl 4-(4- chlorophenyl)-4-(2-hydroxyethyl)piperidine-l-carboxylate (184 mg, 0.541 mmol) in THF (2707 ⁇ ) at rt was added LHMDS (704 ⁇ , 0.704 mmol), and the reaction mixture was stirred at rt for 30 min.
• N-(2,4-dimethoxybenzyl)-2,4,5-trifluoro-N-(l,2,4-thiadiazol-5- yl)benzenesulfonamide (314 mg, 0.704 mmol) was added, and the reaction mixture was stirred at rt for 12 h. Water was added and the aqueous layer was extracted with ethyl acetate (x3). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered, and the filltrate was evaporated in vacuo to give the crude product.
• Step G 4-(2-(4-(4-chlorophenyl)piperidin-4-yl)ethoxy)-2,5-difluoro-N-(l ,2,4-thiadiazol-5- yl)benzenesulfonamide: a solution of tert-butyl 4-(4-chlorophenyl)-4-(2-(4-(N-(2,4- dimethoxybenzyl)-N-(l ,2,4-thiadiazol-5-yl)sulfamoyl)-2,5- difluorophenoxy)ethyl)piperidine- 1 -carboxy late (37 mg, 0.048 mmol) in TFA (121 ⁇ ) was stirred at rt for 30 min.
• Step A tert-Butyl 4-(l-cyano-2-ethoxy-2- oxoethylidene)piperidine-l -carboxylate: To a solution of the tert-butyl 4-oxopiperidine-l - carboxylate (5 g, 25.09 mmol) in benzene (50 mL) was added ethyl cyanoacetate (2.90 g, 25.6 mmol), ammonium acetate (0.542 g, 7.03 mmol) and acetic acid (1.26 mL), and the reaction mixture was heated under reflux for 8 h.
• the raction mixture was diluted with ethyl acetate (100ml), washed with water, 10% sodium bicarbonate solution and brine solution, and dried with sodium sulphate and concentrated to give tert-butyl 4-(l-cyano-2- ethoxy-2-oxoethylidene)piperidine-l-carboxylate (7 g, 98%). This material was used directly foe the next step.
• Step B tert-Butyl 4-(4-chloro-3-fluorophenyl)-4-(l-cyano-2-methoxy-2- oxoethyl)piperidine-l-carboxylate: A few drops of l -chloro-2-fluoro-4-iodobenzene (31.1 g, 121 mmol) in 50 mL of diethyl ether was added to the mixture of magnesium turnings (3.29 g, 136 mmol) and diethyl ether (50 mL) under nitrogen.
• Step C 2-(l -(tert-butoxycarbonyl)-4-(4- chloro-3-fluorophenyl)piperidin-4-yl)-2-cyanoacetic acid: to a solution of tert-butyl 4-(4- chloro-3-fluorophenyl)-4-(l -cyano-2-ethoxy-2-oxoethyl)piperidine-l -carboxylate (12 g, 28.2 mmol) in EtOH (120 mL) was added a solution of NaOH (1 1.30 g, 282 mmol) in water (50 mL), and the reaction mixture was stirred at rt for 12 h.
• Step D tert-Butyl 4-(4-chloro-3-fluorophenyl)-4- (cyanomethyl)piperidine-l-carboxylate: to a solution of 2-(l-(tert-butoxycarbonyl)-4-(4- chloro-3-fluorophenyl)piperidin-4-yl)-2-cyanoacetic acid (11 g, 27.7 mmol) in acetonitrile (110 mL) was added copper(II) oxide (1.030 g, 12.94 mmol), and the reaction mixture was heated under reflux for 30 min. The reaction mixture was filtered through a pad of Celite, and the filtrate was concentrated in vacuo.
• Step E tert-Butyl 4- (4-chloro-3-fluorophenyl)-4-(2-oxoethyl)piperidine-l-carboxylate: to a solution of tert- butyl 4-(4-chloro-3-fluorophenyl)-4-(cyanomethyl)piperidine-l-carboxylate (6.3 g, 17.86 mmol) in DCM (300 mL) at -30 °C was added DIBAL-H ( 1M in toluene) (44.6 mL,
• Step F tert-Butyl 4-(4-chloro-3- fluorophenyl)-4-(2-hydroxyethyl)piperidine-l-carboxylate: to a solution of tert-butyl 4- (4-chloro-3-fluorophenyl)-4-(2-oxoethyl)piperidine-l-carboxylate (3.2 g, 8.99 mmol) in MeOH (32 mL) at 0°C was added NaBH 4 (0.408 g, 10.79 mmol), and the reaction mixture was stirred at 0°C for 30 min.
• Step G tert-butyl 4-(4-chloro-3-fluorophenyl)-4-(2-(4-(N-(2,4- dimethoxybenzyl)-N-(l ,2,4-thiadiazol-5-yl)sulfamoyl)-2,5- difluorophenoxy)ethyl)piperidine-l -carboxylate: to a solution of tert-butyl 4-(4-chloro-3- fluorophenyl)-4-(2-hydroxyethyl)piperidine-l -carboxylate (130 mg, 0.363 mmol), N- (2,4-dimethoxybenzyl)-2,5-difluoro-4-hydroxy-N-(l ,2,4-thiadiazol-5- yl)benzenesulfonamide (177 mg, 0.400 mmol) in THF (2422 ⁇ ) at rt was added DEAD (63.3 ⁇ , 0.400 mmol) ,
• Step H 4-(2-(4-(4-chloro-3-fluorophenyl)piperidin-4-yl)ethoxy)-2,5-difluoro-N- (l,2,4-thiadiazol-5-yl)benzenesulfonamide: to a solution of tert-butyl 4-(4-chloro-3- fluorophenyl)-4-(2-(4-(N-(2,4-dimethoxybenzyl)-N-(l ,2,4-thiadiazol-5-yl)sulfamoyl)-2,5 difluorophenoxy )ethyl)piperi dine- 1-carboxy late (234 mg, 0.299 mmol) in DCM (1992 ⁇ ) at rt was added TFA (230 ⁇ , 2.99 mmol), and the reaction mixture was stirred at rt for 1 h.
• Step A 8-phenyl-8-vinyl-l,4- dioxaspiro[4.5]decane: to a suspension of methyl triphenylphosphonium bromide (19.04 g, 53.3 mmol) in THF (50.8 mL) at -78 °C was added 2.5 M n-BuLi (21.32 ml, 53.3 mmol) dropwise, and a orange nilky suspension was formed.
• the crude product was purified by silica gel chromatography eluting with 0-20% % ethyl acetate/hexanes to give 8-phenyl-8-vinyl-l,4-dioxaspiro[4.5]decane (2 g, 53.8 % yield).
• Step B 2-(8-Phenyl-l,4-dioxaspiro[4.5]decan-8- yl)ethanol: to a solution of 8-phenyl-8-vinyl-l ,4-dioxaspiro[4.5]decane (2 g, 8.19 mmol) in THF (29.2 ml) at rt was added borane THF complex (12.28 ml, 12.28 mmol), and the reaction mxiture was stirred at rt for 1 h. Water was added to quench excessive borane IN sodium hydroxide (13.10 ml, 13.10 mmol) and 37% hydrogen peroxide (33 mL) were added.
• the aqueous layer was extracted with ethyl acetate (x3), and the combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered, and the filltrate was evaporated in vacuo to give the crude product.
• the crude product was purified by silica gel chromatography eluting with 0-40% % ethyl acetate/hexanes to give 2-(8-phenyl-l,4-dioxaspiro[4.5]decan-8-yl)ethanol (1.4 g, 5.34 mmol, 65.2 % yield)as a colorless oil.
• Step C N-(2,4-dimethoxybenzyl)-2,5- difluoro-4-(2-(8-phenyl-l ,4-dioxaspiro[4.5]decan-8-yl)ethoxy)-N-(l ,2,4-thiadiazol-5- yl)benzenesulfonamide: to a solution of 2-(8-phenyl-l,4-dioxaspiro[4.5]decan-8- yl)ethanol (34 mg, 0.130 mmol), N-(2,4-dimethoxybenzyl)-2,5-difluoro-4-hydroxy-N- (l,2,4-thiadiazol-5-yl)benzenesulfonamide (63.2 mg, 0.143 mmol) in THF (864 ⁇ ) at rt was added DEAD (22.57 ⁇ , 0.143 mmol) , and the reaction mixture was stirred at rt for 30 min.
• Step D 2,5-difluoro-4-(2-(4-oxo-l-phenylcyclohexyl)ethoxy)-N-(l,2,4-thiadiazol-5- yl)benzenesulfonamide: to a solution of N-(2,4-dimethoxybenzyl)-2,5-difluoro-4-(2-(8- phenyl-l ,4-dioxaspiro[4.5]decan-8-yl)ethoxy)-N-(l ,2,4-thiadiazol-5- yl)benzenesulfonamide (23 mg, 0.033 mmol) in acetone (669 ⁇ ) at rt was added IN HC1 (134 ⁇ , 0.134 mmol), and the reaction mixture was heated at 60 °C for 1 h.
• Step E 2,5- Difluoro-4-(2-(4-hydroxy-l-phenylcyclohexyl)ethoxy)-N-(l ,2,4-thiadiazol-5- yl)benzenesulfonamide: to a solution of 2,5-difluoro-4-(2-(4-oxo-l - phenylcyclohexyl)ethoxy)-N-(l,2,4-thiadiazol-5-yl)benzenesulfonamide (10 mg, 0.020 mmol) in methanol (405 ⁇ ) at rt was added sodium borohydride (3.07 mg, 0.081 mmol), and the reaction mixture was stirred at rt for 45 min.
• the crude material was purified via preparative LC/MS with the following conditions: Column: XBridge C18, 19 x 200 mm, 5- ⁇ particles; Mobile Phase A: 5 :95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95 :5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 0- 40% B over 20 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the desired product
• Example 51 The following compound was made in a manner analogous to Example 50.
• Example 51 The following compound was made in a manner analogous to Example 50.
• Step A 2-(2-(8-phenyl-l,4-dioxaspiro[4.5]decan- 8-yl)ethyl)isoindoline-l,3-dione: to a solution of 2-(8-phenyl-l,4-dioxaspiro[4.5]decan-8- yl)ethanol (210 mg, 0.800 mmol), isoindoline-l,3-dione (141 mg, 0.961 mmol) and PIBP (252 mg, 0.961 mmol) in THF (4002 ⁇ ) at rt was added DEAD (152 ⁇ , 0.961 mmol), and the reaction mixture was stirred at rt for 12 h.
• This product was purified by preparative TLC on silica gel (0.50 mm thickness) eluting with 40% ethyl acetate/hexanes to give 2-(2-(8-phenyl-l,4-dioxaspiro[4.5]decan-8-yl)ethyl)isoindoline-l,3-dione (325 mg, 0.830 mmol, 104 % yield) as white foam.
• Step B 2-(8-phenyl-l,4-dioxaspiro[4.5]decan-8-yl)ethanamine: to a solution of 2-(2-(8-phenyl-l,4-dioxaspiro[4.5]decan-8-yl)ethyl)isoindoline-l ,3-dione (325 mg, 0.830 mmol) in methanol/THF (1 : 1) (4151 ⁇ ) at rt was added hydrazine hydrate (604 ⁇ , 12.45 mmol), and the reaction mixture was stirred at rt for 12 h. White precipitate was formed 2 h after addition.
• Step C 5-chloro-N-(2,4- dimethoxybenzyl)-2-fluoro-4-((2-(8-phenyl-l,4-dioxaspiro[4.5]decan-8-yl)ethyl)amino)- N-(thiazol-2-yl)benzenesulfonamide: a mixture of 2-(8-phenyl-l,4-dioxaspiro[4.5]decan- 8-yl)ethanamine (217 mg, 0.830 mmol), 5-chloro-N-(2,4-dimethoxybenzyl)-2,4-difluoro- N-(thiazol-2-yl)benzenesulfonamide (402 mg, 0.872 mmol) and cesium carbonate (298
• Step D 5-chloro-2-fluoro-4-((2-(4- oxo-1 -phenylcyclohexyl)ethyl)amino)-N-(thiazol-2-yl)benzenesulfonamide: a solution of 5-chloro-N-(2,4-dimethoxybenzyl)-2-fluoro-4-((2-(8-phenyl-l ,4-dioxaspiro[4.5]decan-8- yl)ethyl)amino)-N-(thiazol-2-yl)benzenesulfonamide (71 mg, 0.101 mmol) and HC1 (404 ⁇ , 0.404 mmol) in acetone (2022 ⁇ ) was heated under reflux for 2 h.
• Step E 4-(2-(4-Amino-l -phenylcyclohexyl)ethoxy)-5-chloro-2-fluoro-N-(l ,2,4- thiadiazol-5-yl)benzenesulfonamide: a mixture of 5-chloro-2-fluoro-4-((2-(4-oxo-l- phenylcyclohexyl)ethyl)amino)-N-(thiazol-2-yl)benzenesulfonamide (50 mg, 0.098 mmol), ammonium acetate (76 mg, 0.984 mmol), sodium cyanoborohydride (12.37 mg, 0.197 mmol) and 4A MS in methanol (656 ⁇ ) was stirred at rt for 2 h.
• Step A Diethyl 2-(4-((tert- butoxycarbonyl)amino)cyclohexylidene)malonate: to an ice-cold soln of tert-butyl (4- oxocyclohexyl)carbamate (480 mg, 2.251 mmol) in THF (1 mL) were added dropwise 1.0 M TiC in DCM (5.63 mL, 5.63 mmol), diethyl malonate (721 mg, 4.50 mmol) and pyridine (1.456 mL, 18.01 mmol), and the mixture was stirred at 0 °C for 30 min and then rt for 4 h.
• Step B Diethyl 2-(4-((tert-butoxycarbonyl)amino)-l-methylcyclohexyl)malonate: to a suspension of copper (I) iodide (190 mg, 0.999 mmol) in THF (4 mL) were added dropwise 3.0 M MeMgBr in THF (0.999 mL, 3.00 mmol) at -50 °C, and the reaction mixture was warmed up to rt and stirred at rt for 10 min.
• Step C 2-(4-((tert-Butoxycarbonyl)amino)-l- methylcyclohexyl)malonic acid: to a solution of diethyl 2-(4-((tert- butoxycarbonyl)amino)-l-methylcyclohexyl)malonate (350 mg, 0.942 mmol) in THF (4 mL) were added a solution of LiOH (226 mg, 9.42 mmol) in water (1 mL), and 1 mL of MeOH was added to make a homogeneous solution. The mixture was stirred at 55 °C for 18 h and then at 90 °C for 5 h.
• Step D 2-(4-((tert-Butoxycarbonyl)amino)-l-methylcyclohexyl)acetic acid: a solution of the crude 2-(4-((tert-butoxycarbonyl)amino)-l-methylcyclohexyl)malonic acid (236 mg, 0.748 mmol) in DMF (4 niL) was stirred at 100 °C oil bath for 18 h. The mixture was then concentrated in vacuo to give a crude 2-(4-((tert- butoxycarbonyl)amino)-l-methylcyclohexyl)acetic acid (203 mg, 100 % yield). This crude material was used for the next step without any purification.
• Step E tert-Butyl (4- (2-hydroxyethyl)-4-methylcyclohexyl)carbamate: to a solution of 2-(4-((tert- butoxycarbonyl)amino)-l-methylcyclohexyl)acetic acid (100 mg, 0.369 mmol) in THF (1.5 mL) was added N-methylmorpholine (0.065 mL, 0.590 mmol) followed by isobutyl chloroformate (0.063 mL, 0.479 mmol) in an ice-salt bath, and the reaction mixture was stirred at 0 °C for 2 h.
• the reaction mixture was filtered, and the filtrate was added to a solution of NaBH 4 (34.9 mg, 0.921 mmol) in 0.5 mL of THF and 0.2 mL of water at 10 °C, and the reaction mixture was stirred at rt for 1 h. Water was added, the aqueous layer was extracted with ethyl acetate, and the combined organic layers were dried over sodium sulfate, and concentrated. The residue was purified via silica gel chromatography (Biotage 4g, hexanes-100%EtOAc) to give tert-butyl (4-(2-hydroxyethyl)-4- methylcyclohexyl)carbamate (65 mg, 69 % yield).
• Step F tert-Butyl (4-(2-(4-(N-(2,4-dimethoxybenzyl)- N-(l,2,4-thiadiazol-5-yl)sulfamoyl)-2,5-difluorophenoxy)ethyl)-4- methylcyclohexyl)carbamate: to a solution of tert-butyl (4-(2-hydroxyethyl)-4- methylcyclohexyl)carbamate (25 mg, 0.097 mmol), N-(2,4-dimethoxybenzyl)-2,5- difluoro-4-hydroxy-N-(l ,2,4-thiadiazol-5-yl)benzenesulfonamide (51.7 mg, 0.117 mmol) and Ph 3 P (38.2 mg, 0.146 mmol) in THF (0.5 mL) was added DEAD (0.023 mL, 0.146 mmol) at
• Step G 4-(2-(4-amino-l - methylcyclohexyl)ethoxy)-2,5-difluoro-N-(l,2,4-thiadiazol-5-yl)benzenesulfonamide: a solution of tert-butyl (4-(2-(4-(N-(2,4-dimethoxybenzyl)-N-(l,2,4-thiadiazol-5- yl)sulfamoyl)-2,5-difluorophenoxy)ethyl)-4-methylcyclohexyl)carbamate (50 mg, 0.073 mmol) TFA (0.113 mL, 1.465 mmol) in DCM (0.5 mL) was stirred at rt for 3 h.
• Example 58 The following compounds were made in a manner analogous to Example 49.
• Example 58 and Example 59 The following compounds were made in a manner analogous to Example 49.
• Example 58 and Example 59
• Step A Ethyl 2-(4-((tert- butoxycarbonyl)amino)cyclohexylidene)acetate: to a suspension ofNaH (0.518 g, 12.94 mmol) in THF (20 mL) was added ethyl 2-(diethoxyphosphoryl)acetate (2.78 g, 12.38 mmol) dropwise at rt.
• reaction mixture was stirred at rt for 20 min and the cooled to 0°C, and tert-butyl (4-oxocyclohexyl)carbamate (2.4 g, 11.25 mmol) was added.
• the reaction mixture was stirred at rt for 1 h, and the THF solution was decanted. The residue was dissolved into 50 mL of water, the aqueous layer was extracted with ether, and the combined organic layers were concentrated.
• Step B Ethyl 2-(4-((tert- butoxycarbonyl)amino)cyclohexyl)acetate: a mixture of 10% PdVC (200 mg, 0.188 mmol) and ethyl 2-(4-((tert-butoxycarbonyl)amino)cyclohexylidene)acetate (1.0 g, 3.53 mmol) in methanol (10 mL) was stirred at rt under hydrogen baloon for 5 h. The reaction mixture was filtered, and the filtrate was concentrated to give ethyl 2-(4-((tert- butoxycarbonyl)amino)cyclohexyl)acetate (1.00 g, 100 % yield).
• Step C tert-Butyl (4-(2-hydroxyethyl)cyclohexyl)carbamate: to a solotion of ethyl 2-(4-((tert-butoxycarbonyl)amino)cyclohexyl)acetate (340 mg, 1.19 mmol) in THF (5 mL) was added 2.0 M LAH in THF (0.596 mL, 1.191 mmol) under N2 at -40 °C. The mixture was allowed to warm up to 10 °C. 30 mL of ether was added followed by Na2SO4.10H2O. The mixture was stirred at rt for 1 h, and the solid was removed via Alteration.
• Step D N-(2,4-dimethoxybenzyl)-2,5- difluoro-4-hydroxy-N-(l ,2,4-thiadiazol-5-yl)benzenesulfonarnide: to a solution of N- (2,4-dimethoxybenzyl)-2,4,5 rifluoro-N-(l,2,4-thiadiazol-5-yl)benzenesulfonamide (1 g, 2.245 mmol) and 2-(methylsulfonyl)ethanol (0.419 ml, 4.49 mmol) in DMSO (5.61 ml) at rt was added potassium tert-butoxide (0.630 g, 5.61 mmol), and the reaction mixture was stirred at rt for 1 h.
• Step E tert-Butyl (4-(2-(4-(N- (2,4-dimethoxybenzyl)-N-(l ,2,4-thiadiazol-5-yl)sulfamoyl)-2,5- difluorophenoxy)ethyl)cyclohexyl)carbamate: to a solution of tert-butyl (4-(2- hydroxyethyl)cyclohexyl)carbamate (40 mg, 0.164 mmol), N-(2,4-dimethoxybenzyl)-2,5- difluoro-4-hydroxy-N-(l ,2,4-thiadiazol-5-yl)benzenesulfonamide (87 mg, 0.197 mmol) and «-Bu3Ph (49.9 mg, 0.247 mmol) in THF (1 mL) was added DIAMIDE (42.5 mg, 0.247 mmol) at rt, and the reaction mixture was stirred at rt for 3 h and at
• Step F 4-(2-(4- Aminocyclohexyl)ethoxy)-2,5-difluoro-N-(l,2,4-thiadiazol-5-yl)benzenesulfonamide: to a solution of tert-butyl (4-(2-(4-(N-(2,4-dimethoxybenzyl)-N-(l,2,4-thiadiazol-5- yl)sulfamoyl)-2,5-difluorophenoxy)ethyl)cyclohexyl)carbamate (95 mg, 0.142 mmol) in DCM (1 mL) were added TFA (0.219 mL, 2.84 mmol) at rt.
• Step C (8-(4-chloro-3-fluorobenzyl)-l,4- dioxaspiro[4.5]decan-8-yl)methanol: to a solution of ethyl 8-(4-chloro-3-fluorobenzyl)- l,4-dioxaspiro[4.5]decane-8-carboxylate (1.86 g, 5.21 mmol) in ether (52.1 ml) at 0 °C was added L1AIH4 (0.198 g, 5.21 mmol) portionwise, and the reaction mixture was stirred at 0 °C for 30 min.
• Step D 4-((8-(4-chloro-3-fluorobenzyl)- l ,4-dioxaspiro[4.5]decan-8-yl)methoxy)-N-(2,4-dimethoxybenzyl)-2,5-difluoro-N-(l,2,4- thiadiazol-5-yl)benzenesulfonamide: to a solution of (8-(4-chloro-3-fluorobenzyl)-l ,4- dioxaspiro[4.5]decan-8-yl)methanol (1 g, 3.18 mmol) in THF (15.88 ml) at rt was added LHMDS (4.13 ml, 4.13 mmol), and the reaction mixture was stirred at rt for 30 min.
• Step E 4-((l-(4-chloro-3-fluorobenzyl)-4- oxocyclohexyl)methoxy)-2,5-difluoro-N-(l ,2,4-thiadiazol-5-yl)benzenesulfonamide: to a solution of 4-((8-(4-chloro-3-fluorobenzyl)-l ,4-dioxaspiro[4.5]decan-8-yl)methoxy)-N- (2,4-dimethoxybenzyl)-2,5-difluoro-N-(l ,2,4-thiadiazol-5-yl)benzenesulfonamide (1.67 g, 2.256 mmol) in acetone (45.1 ml) at rt was added HC1 (9.02 ml, 9.02 mmol) , and the reaction mixture was heated at 60 °C for 1 h.
• Step F 4-((4-amino-l - (4-chloro-3-fluorobenzyl)cyclohexyl)methoxy)-2,5-difluoro-N-(l,2,4-thiadiazol-5- yl)benzenesulfonamide: a solution of 4-((l-(4-chloro-3-fluorobenzyl)-4- oxocyclohexyl)methoxy)-2,5-difluoro-N-(l ,2,4-thiadiazol-5-yl)benzenesulfonamide (100 mg, 0.183 mmol), ammonium acetate (141 mg, 1.832 mmol) , 4A MS (4 pieces), sodium borohydride (26.5 mg, 0.421 mmol) in methanol (916 ⁇ ) was stirred at rt for 2 h. The crude material was purified via preparative LC/MS with the following conditions:
• the crude material was purified via preparative LC/MS with the following conditions: Column: XBridge C18, 19 x 200 mm, 5- ⁇ particles; Mobile Phase A: 5 :95 methanol: water with 10-mM ammonium acetate; Mobile Phase B: 95 :5 methanol: water with 10- mM ammonium acetate; Gradient: 35-85% B over 30 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Neurosurgery (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
• Plural Heterocyclic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Publications (1)

Family

ID=60245256

Family Applications (1)

Country Status (8)

Cited By (8)

Citations (2)

Family Cites Families (7)

• 2017
  • 2017-10-26 MA MA046615A patent/MA46615A/fr unknown
  • 2017-10-26 US US16/344,414 patent/US10836758B2/en active Active
  • 2017-10-26 CN CN201780079199.3A patent/CN110088093B/zh active Active
  • 2017-10-26 KR KR1020197014690A patent/KR102561076B1/ko active Active
  • 2017-10-26 JP JP2019523090A patent/JP7072569B2/ja active Active
  • 2017-10-26 ES ES17794203T patent/ES2897998T3/es active Active
  • 2017-10-26 WO PCT/US2017/058472 patent/WO2018081384A1/en not_active Ceased
  • 2017-10-26 EP EP17794203.4A patent/EP3532462B1/en active Active

Patent Citations (2)

Non-Patent Citations (41)

Also Published As

Similar Documents

Legal Events